Now we will discuss the financial strength of Flexion Therapeutics, Inc. (NASDAQ:FLXN) are making a strong comeback as they have jumped 61.71% since bottoming out at $15.93 on November 08, 2016. The company shares sank -18.73% from their peak of $32.25 and now has a $834.16 million market value of equity.
Other research analysts also recently issued research reports about the stock. Royal Bank Of Canada restated an outperform rating and set a $44.00 price target on shares of Flexion Therapeutics in a research note on Thursday, August 10th. In that case, its shares would mark a 4% decline from the most recent price. The correct version of this piece can be read at https://weekherald.com/2017/10/12/zacks-investment-research-upgrades-flexion-therapeutics-inc-flxn-to-hold.html.
Some buy side analysts are also providing their Analysis on Flexion Therapeutics, Inc., where 4 analysts have rated the stock as Strong buy, 4 analysts have given a Buy signal, 0 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. Flexion Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $29.23.
Shares of Flexion Therapeutics (NASDAQ:FLXN) now have an Average Brokerage Recommendation of 1.17, number of Recs in ABR is 6 while industry rank of the company by ABR is 162 out of 265.
In other news, insider Yamo Deniz bought 3,000 shares of the stock in a transaction that occurred on Friday, September 1st. The firm's market capitalization is $850.27 million.
Moving average is significant analytical tool used to discover current price trends and the possibility for a change in an established trend.
Flexion Therapeutics (NASDAQ:FLXN) traded down 0.316% on Wednesday, hitting $17.365.
The company's Average Earnings Estimate for the Current Fiscal quarter is $-1.15, according to consensus of 9 analysts.
08/24/2017 - Northland Securities began new coverage on Flexion Therapeutics Inc giving the company a "outperform" rating. Finally, BMO Capital Markets reissued a "buy" rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and global trademark and copyright law. The value of the total investment in Flexion Therapeutics, Inc. went from $15,000 to $57,000 increasing 280.0% since the last quarter. The shares were acquired at an average cost of $24.15 per share, for a total transaction of $72,450.00. Following the completion of the purchase, the insider now directly owns 5,000 shares of the company's stock, valued at $120,750. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. For the past 5 years, the company's revenue has grown 138.7%, while the company's earnings per share has grown -8.1%. This activity represents a continuation of a theme over the past twelve months. Finally, The Manufacturers Life Insurance Company boosted its stake in Flexion Therapeutics by 3.9% during the second quarter. Company shares last traded at $25.76 slightly over $25.14, the stock's 50 day moving average and a great deal higher than the 200 day moving average of $22.67. Asset Management One Co. Public Employees Retirement System of OH boosted its stake in Flexion Therapeutics by 69.4% during the second quarter. Voya Investment Management LLC lifted its holdings in Flexion Therapeutics by 25.8% during the 2nd quarter. The stock volatility for the week was 12.46% while for the month was 6.50%. In the most recent quarter, institutional ownership increased by a net of 2.46 million shares, or 9.29%.This is a bullish sign and indicates that institutions are feeling more optimistic about the outlook for FLXN overall.64 holders increased their positions, 43 decreased their positions, and 14 holders held their positions.
Flexion Therapeutics, Inc.is a United States-based specialty pharmaceutical company.